Clinical trials: Traveler's Diarrhea
Travelers' Diarrhea
A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
This study compared safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea.
- Trial name
- NCT02920242
- Testing
- Rifaximin (Sandoz GmbH) tablet, Rifaximin (Xifaxan)
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Sandoz
Travelers' Diarrhea
Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea
Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of…
- Trial name
- NCT00292344
- Testing
- Rifaximin and loperamide
- Where
- 4 sites in Mexico
- Volunteers
- 316 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Watery Diarrhea, Dysentery/Febrile Diarrhea
Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea
The purpose of the trial is to develop the evidence on relative efficacy of 3 available single-dose loperamide adjuncted regimens for watery diarrhea and a single-dose regimen, with and without loperamide, for dysentery/febrile…
- Trial name
- TrEAT TD (NCT01618591)
- Testing
- Single dose rifaximin 1650 mg, Single dose azithromycin 500 mg, Single dose levofloxacin 500 mg
- Where
- 5 sites in Afghanistan, Djibouti and 3 more
- Volunteers
- 384 people
- Sponsor
- Uniformed Services University of the Health Sciences
Acute Bacterial Gastroenteritis
Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers
The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of patients with acute bacterial gastroenteritis (traveler's diarrhea.
- Trial name
- NCT00448422
- Testing
- prulifloxacin
- Where
- India
- Volunteers
- 268 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Traveler's Diarrhea
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.
- Trial name
- NCT01142089
- Testing
- Rifamycin SV MMX
- Where
- 12 sites in Guatemala, Mexico
- Volunteers
- 264 people
- Sponsor
- Cosmo Technologies Ltd
Traveler's Diarrhea
PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli
The APA12/PANTER study is a parallel 3-weeks intervention study. Subjects will be randomly assigned to one of two treatment groups; placebo or PTM202 (n=36 per group).
- Trial name
- APA12/PANTER (NCT03301103)
- Testing
- E. coli strain E1392-75-2A, PTM202
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Travelers' Diarrhea, Functional Bowel Disorders
Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD
The purpose of this study is to develop evidence on the relative efficacy of 2 rifaximin chemoprophylaxis regimens for the prevention of Travelers' Diarrhea (TD) in a deployed setting.
- Conditions
- Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
- Trial name
- NCT02498301
- Testing
- Rifaximin
- Where
- 6 sites in United States, Kenya
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Diarrhea
Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I
The purpose of this study is to assess anti-CFA/I and anti-CfaE BIgG safety and to determine protective efficacy of anti-CFA/I and anti-CfaE BIgG against diarrhea after challenge with H10407, a CFA/I-expressing ETEC strain.
- Trial name
- BIgGI (NCT00435526)
- Testing
- anti-CFA/I bovine IgG, and anti-CfaE bovine IgG
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diarrhea, Travelers Diarrhea
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
This is a randomized, double-blind, placebo-controlled study to investigate a single daily dose of Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli…
- Conditions
- Diarrhea, Travelers Diarrhea, Infectious Diarrhea
- Trial name
- NCT05933525
- Testing
- Travelan
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Immuron Ltd.
Diarrhoea;Acute, Diarrhea Travelers
Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
The purpose of this study is to compare a single dose of rifaximin with loperamide to the current standard approach of single dose azithromycin with loperamide for the treatment of acute watery traveler's diarrhea (TD).
- Trial name
- TrEAT_TD2 (NCT05677282)
- Testing
- Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
- Where
- 4 sites in Djibouti, Honduras and 2 more
- Volunteers
- 150 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Travelers' Diarrhea
Probiotics and the Prevention of Traveler's Diarrhea
The present study is designed to evaluate the effect of a mixture of probiotics on the prevention of traveler's diarrhea (TD) in subjects who travel to a country with a high risk for developing TD.
- Trial name
- TD (NCT01005849)
- Testing
- Protecflor
- Where
- Italy
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Lallemand SAS
Diarrhea
Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
The purpose of this study is to determine the efficacy of Bio-K+ CL1285 in reducing traveler's diarrhea.
- Trial name
- NCT00737412
- Testing
- Probiotic: Bio-K+ CL1285
- Where
- 4 sites in Canada
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Traveler's Diarrhea
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.
- Trial name
- ERASE (NCT01208922)
- Testing
- Rifamycin SV-MMX®, Ciprofloxacin
- Where
- 19 sites in Ecuador, Guatemala and 1 more
- Volunteers
- 835 people
- Sponsor
- Dr. Falk Pharma GmbH
Traveler's Diarrhea
Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
This will be a double-blind comparative study, performed in pediatric subjects (Age 6-11) traveling to developing regions with a known high incidence of traveler's diarrhea.
- Trial name
- NCT04026984
- Testing
- Rifamycin SV-MMX
- Volunteers
- 142 people
- Sponsor
- RedHill Biopharma Limited
Travelers Diarrhea
Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia
The study proposed here will determine the frequency and etiology of diarrhea in Australian adult tourists traveling to Southeast Asia, including Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand…
- Trial name
- AusTD (NCT06363890)
- Testing
- TAQMan Array Card
- Where
- Australia
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Traveler's Diarrhea
Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study
The purpose of this study is to evaluate the efficacy of the TD Vaccine System to prevent moderate to severe enterotoxin E.coli (ETEC) disease in travelers to India.
- Trial name
- NCT01040325
- Testing
- TD Vaccine System
- Where
- 12 sites in Germany, India and 1 more
- Volunteers
- 723 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Travelers Diarrhea
G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
The goal of this interventional study is to learn about the intraluminal pharmacokinetics (PK) of the investigational drug LMN-401 in adult healthy volunteers with ileostomies.
- Trial name
- NCT06556940
- Testing
- LMN-401
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Traveler's Diarrhea
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea.
- Trial name
- NCT04027894
- Testing
- Rifamycin SV MMX
- Volunteers
- 142 people
- Sponsor
- RedHill Biopharma Limited
Diarrhea
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD)…
- Trial name
- NCT00328380
- Testing
- Rifaximin
- Where
- 3 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Travelers' Diarrhea
Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD
This is a Phase II, randomized, double-blind, placebo-controlled study designed to investigate whether hyperimmune bovine milk IgG products specific for CsbD and CS17, protect subjects against diarrhea upon challenge with a…
- Trial name
- BIgGII (NCT00524004)
- Testing
- Anti-CsbD Bovine IgG, Anti-CS17 Bovin IgG
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health